New drug combo aims to slow advanced colorectal cancer
NCT ID NCT06992258
First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests whether adding a second drug (TAS-102) to the standard drug fruquintinib helps people with advanced colorectal cancer live longer without their cancer growing. About 120 adults whose cancer has not responded to prior treatments will be randomly assigned to receive either the combination or fruquintinib alone. The main goal is to see if the combination delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Schar Cancer
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mays Cancer Center at University of Texas Health at San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mount Sinai Cancer Research Program
RECRUITINGMiami Beach, Florida, 33140, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Orlando Health Cancer Institute
RECRUITINGOrlando, Florida, 32806, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Email: •••••@•••••
-
UPenn Lancaster-Ann B. Barshinger Cancer Institute
RECRUITINGLancaster, Pennsylvania, 17601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.